Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. - Wikidata - awgldk - TriplyDB

Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents.

Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents.

http://www.wikidata.org/entity/Q37378187

about

TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice Glioblastoma Stem Cells Microenvironment: The Paracrine Roles of the Niche in Drug and Radioresistance A role for G-CSF and GM-CSF in nonmyeloid cancers Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.Anti-VEGF-A affects the angiogenic properties of tumor-derived microparticles Enhanced antitumor efficacy of a vascular disrupting agent combined with an antiangiogenic in a rat liver tumor model evaluated by multiparametric MRI Opportunities and challenges for successful use of bevacizumab in pediatrics.Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas.Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes Influence of soluble or matrix-bound isoforms of vascular endothelial growth factor-A on tumor response to vascular-targeted strategies.A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate.Moving forward with metronomic chemotherapy: meeting report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology.G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA.A Pilot Study of Circulating Endothelial and Hematopoietic Progenitor Cells in Children With Sarcomas.CSF2 Overexpression Is Associated with STAT5 Phosphorylation and Poor Prognosis in Patients with Urothelial Carcinoma.A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.Hitting Them Where They Live: Targeting the Glioblastoma Perivascular Stem Cell Niche.NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells.Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.Macrophage-Induced Lymphangiogenesis and Metastasis following Paclitaxel Chemotherapy Is Regulated by VEGFR3 Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models.Treatment with the vascular disruptive agent OXi4503 induces an immediate and widespread epithelial to mesenchymal transition in the surviving tumor.The antiangiogenic role of the pro-inflammatory cytokine interleukin-31.New anti-angiogenic strategies in pediatric solid malignancies: agents and biomarkers of a near future.Mechanisms of resistance to vascular endothelial growth factor blockade.The impact of tumor microenvironment on cancer treatment and its modulation by direct and indirect antivascular strategies.Treatment-induced host-mediated mechanisms reducing the efficacy of antitumor therapies.Combretastatin A4 phosphate treatment induces vasculogenic mimicry formation of W256 breast carcinoma tumor in vitro and in vivo.Tumor-derived microparticles induce bone marrow-derived cell mobilization and tumor homing: a process regulated by osteopontin.Dose- and time-dependence of the host-mediated response to paclitaxel therapy: a mathematical modeling approach.

P2860

Q24606406-46B1D464-6E46-4C4C-850C-AF17D4B103CC Q26765869-D4220A2C-805C-45DA-A3FA-01996FC9685F Q27002515-BC2D8BF0-812F-42D1-9235-A8A117315192 Q27853358-AF744931-0392-47FF-AC8E-E349E93CEF20 Q28538098-C5330860-C504-47B7-8852-3086CF964BB1 Q28729080-5B33DB34-E90F-4823-9AC9-E9057DD735D9 Q30454883-D7336E0C-BC87-42EE-A9CC-83EE5A76E100 Q33587106-CFAC56DE-8A54-426D-8245-A3C791D3A8C1 Q34411361-A758BB5D-E52B-439D-987B-E90FAB4EAFBA Q34742649-53199241-4D6A-46ED-A85C-C5CF0091F86A Q34765364-EFE067ED-93B1-4C79-90AB-E2192FFD86F0 Q34810458-182ED717-2A20-49BF-8192-EEE36C3F66D1 Q34954063-8AA5D84C-069A-47D0-92AC-6F8AEA792166 Q35116804-0DE133ED-0A31-4016-93DE-138FC5D701A0 Q35230245-EC7DEE9F-0C76-4900-91D9-13646A6D9FEF Q35832390-64F93393-11F9-4B6A-95EB-D9E555CE8F36 Q35862618-5ECCB66F-51F7-4FB9-89CC-A36D81EC64B3 Q35989342-7D00002B-B50A-4A33-BF73-A04BB5BF8D5A Q36163040-578A9566-EE64-40C8-9A13-AF544410626D Q36916624-878FC98D-C73B-4137-B232-79017226896A Q37043370-0551F594-E1BF-499B-8842-D2FABCB4452B Q37154148-A7A14F87-7974-41F9-8D17-E0AD92D3C53F Q37397162-4FF8A04D-CE1B-46E4-9ECA-71630CC6AF75 Q37435219-E8CB558E-99AC-46F7-8AF5-4FF0E63562AE Q37482536-35D68CC6-C5B3-48BE-8EBF-1DE0A85B8C7A Q37725449-490D0384-5443-461F-886A-6803DE89F37B Q37752435-E371538D-E757-49F1-908F-DFE3A956D000 Q37956587-D0073815-AA71-439D-B764-01AFFD158F1C Q38028791-5B879BFD-0141-4079-B7CC-9738EBAF798C Q38092582-677919F5-EEE7-4555-889C-422DCA2E257D Q38869295-B7476CAB-A121-4A30-B7D4-3ACA762A69DF Q39042430-ECCC9747-A762-4B34-AFF2-171C19FB8E01 Q49636757-45E10BC5-8BA2-4866-A583-455E668168E7

P2860

Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents.

http://www.wikidata.org/entity/Q37378187

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 08 September 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Contribution of granulocyte co ...... by vascular disrupting agents.

@en

Contribution of granulocyte co ...... by vascular disrupting agents.

@nl

type

label

Contribution of granulocyte co ...... by vascular disrupting agents.

@en

Contribution of granulocyte co ...... by vascular disrupting agents.

@nl

prefLabel

Contribution of granulocyte co ...... by vascular disrupting agents.

@en

Contribution of granulocyte co ...... by vascular disrupting agents.

@nl

P1433

Q37378187-355F8EF2-3E2F-4518-82B3-B0074A6282B9

P1476

Q37378187-0E902DD1-DEBE-497B-A3DB-722279A273D3

P2093

Q37378187-01F586FA-5CC7-44E1-A697-B367EFB613E8

Q37378187-062485D1-24F6-425D-901B-3F2112AD8FBF

Q37378187-3666BF1E-6A0F-4899-BFDC-596749860BBB

Q37378187-584B32A8-13E4-4F2B-B63B-8251AFBE8EA2

Q37378187-58A53022-A09D-4761-BC90-899F37798767

Q37378187-66A8369B-5B4A-4367-AE87-942D6B52C510

Q37378187-7BB4F3EE-574C-456B-B93B-1DB59563A81F

Q37378187-847800B4-8463-4EF2-AC7F-3A1365856A2C

Q37378187-90D52CC4-ABB7-46FD-B582-C91780489B7C

Q37378187-B5EA6875-31A8-4A50-9B6E-00585DAE31A3

P2860

Q37378187-014A133C-580B-4F4D-9D35-BCF12C3B8167

Q37378187-0BE43F8E-01FF-4340-803D-80703F22771A

Q37378187-15F9C55B-7926-4C35-A7B7-42E4142A1ABC

Q37378187-160BD560-627B-4229-922B-0B7F6ABFB7CD

Q37378187-22CFF361-CB96-4EA1-BF5C-005E23B6F1F5

Q37378187-33679CCB-92E1-4E75-B8F1-2B90F3A06BF2

Q37378187-37ED8B1A-9057-4ECA-BA60-2898881B6AB7

Q37378187-40D8259A-5E1D-481D-93D8-5E14065320AE

Q37378187-555AAA02-2765-45D2-A5B3-75AF4BAD82CD

Q37378187-639E6D60-1E78-4188-9C5A-168B56EAB1F5

P304

Q37378187-F999ABEE-A17E-4A72-92C4-12CCEF33D945

P31

Q37378187-14319DC7-DC9C-48DF-AEF3-DA33AD3CA94A

P356

Q37378187-50662575-92B5-4E50-9F71-79C40388F260

P407

Q37378187-C4B90808-9407-4456-AD73-84C172C6D557

P433

Q37378187-2FACDBDF-340D-4EA2-984A-257149B0E27C

P478

Q37378187-EBF027B9-FEA1-4013-A697-82AFB234960C

P50

Q37378187-7A36C0E7-39C1-46C0-AE5D-22B4B87D99D8

Q37378187-87A8AEA4-0C97-43E7-913B-D559CE86B3B2

P577

Q37378187-4EC0D94E-4A73-4108-92DE-5C432E3346CA

P698

Q37378187-913823E2-A597-4EF7-8D16-73754FF80492

P921

Q37378187-3CB51859-739E-4C7E-9940-0FA3DC0ABA2B

P932

Q37378187-542351CA-83E9-4534-B957-C8D52C350010

P356

0008-5472.CAN-09-0381

P1433

Cancer Research

P1476

Contribution of granulocyte co ...... by vascular disrupting agents

@en

P2093

Daniel C Link

http://www.w3.org/2001/XMLSchema#string

David J Chaplin

http://www.w3.org/2001/XMLSchema#string

Emile E Voest

http://www.w3.org/2001/XMLSchema#string

Gordon Rustin

http://www.w3.org/2001/XMLSchema#string

Ian Judson

http://www.w3.org/2001/XMLSchema#string

Jeffrey M Arbeit

http://www.w3.org/2001/XMLSchema#string

Jill Woloszynek

http://www.w3.org/2001/XMLSchema#string

Jon Smythe

http://www.w3.org/2001/XMLSchema#string

Laura G Daenen

http://www.w3.org/2001/XMLSchema#string

Paul Nathan

http://www.w3.org/2001/XMLSchema#string

P2860

Tumor angiogenesis: therapeutic implications

Isolation of putative progenitor endothelial cells for angiogenesis

Differential mobilization of subsets of progenitor cells from the bone marrow

Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.

Disrupting tumour blood vessels.

Clinical implications of antiangiogenic therapies.

Repopulation of cancer cells during therapy: an important cause of treatment failure.

The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death.

The multifaceted circulating endothelial cell in cancer: towards marker and target identification.

CXCR4 is a key regulator of neutrophil release from the bone marrow under basal and stress granulopoiesis conditions.

P304

7524-7528

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-09-0381

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P50

Adrian L Harris

Francesco Bertolini

P577

2009-09-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19738066

http://www.w3.org/2001/XMLSchema#string

P921

P932

2758166

http://www.w3.org/2001/XMLSchema#string